"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares the initial and ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter. To help answer this question, we should first ...

Wilms tumor growth patterns differ based on the specific predisposition gene variant and its developmental timing. Around 30% of children with Wilms tumor have a mutation in a predisposition gene, ...

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD. In this video, Timothy D. Lyon, MD, discusses the Urology Practice ...

Prostate cancer incidence and mortality are increasing, with over 313,000 diagnoses and 35,000 deaths projected for 2025. Screening practices, influenced by the US Preventive Services Task Force, have ...

"I would say the fact that we performed 754 HoLEP procedures in 2024 is a reflection of the efficiency and the high quality of care that you receive at Northwestern," says Amy E. Krambeck, MD. In this ...

"The idea here is to determine, from an epidemiologic perspective, whether freezing sperm for many men before their vasectomy is cost-effective compared to whether we should simply avoid this routine ...

MPS2 test detects 94% of GG2 or higher prostate cancers using non-DRE urine samples, outperforming PSA and PCPTrc in accuracy. MPS2 models could reduce unnecessary biopsies by 36% to 42%, compared to ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

Urology Coding Q&A: Can G2211 be reported regardless of payer?

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...